NO20003211L - Triazinforbindelser for behandling av CNS forstyrrelser - Google Patents

Triazinforbindelser for behandling av CNS forstyrrelser

Info

Publication number
NO20003211L
NO20003211L NO20003211A NO20003211A NO20003211L NO 20003211 L NO20003211 L NO 20003211L NO 20003211 A NO20003211 A NO 20003211A NO 20003211 A NO20003211 A NO 20003211A NO 20003211 L NO20003211 L NO 20003211L
Authority
NO
Norway
Prior art keywords
treatment
cns disorders
triazine compounds
triazine
cns
Prior art date
Application number
NO20003211A
Other languages
English (en)
Other versions
NO20003211D0 (no
Inventor
Brian Cox
Mark Patrick Healy
Malcolm Stuart Nobbs
Gita Punjabhai Shah
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20003211D0 publication Critical patent/NO20003211D0/no
Publication of NO20003211L publication Critical patent/NO20003211L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En forbindelse ifølge formel (I) og farmasøytisk akseptable promedikamenter, salter og solvater derav er beskrevet.
NO20003211A 1997-12-22 2000-06-21 Triazinforbindelser for behandling av CNS forstyrrelser NO20003211L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726987.2A GB9726987D0 (en) 1997-12-22 1997-12-22 Compounds
PCT/EP1998/008273 WO1999032462A1 (en) 1997-12-22 1998-12-18 Triazine compounds for treatment of cns disorders

Publications (2)

Publication Number Publication Date
NO20003211D0 NO20003211D0 (no) 2000-06-21
NO20003211L true NO20003211L (no) 2000-08-21

Family

ID=10823992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003211A NO20003211L (no) 1997-12-22 2000-06-21 Triazinforbindelser for behandling av CNS forstyrrelser

Country Status (34)

Country Link
US (2) US6265405B1 (no)
EP (1) EP1042304A1 (no)
JP (1) JP2001526275A (no)
KR (1) KR20010024800A (no)
CN (1) CN1284951A (no)
AP (1) AP2000001846A0 (no)
AR (1) AR014146A1 (no)
AU (1) AU753874B2 (no)
BR (1) BR9814495A (no)
CA (1) CA2315620A1 (no)
CO (1) CO5011066A1 (no)
EA (1) EA200000561A1 (no)
EE (1) EE200000391A (no)
GB (1) GB9726987D0 (no)
GT (1) GT199800203A (no)
HN (1) HN1998000193A (no)
HR (1) HRP20000419A2 (no)
HU (1) HUP0100611A3 (no)
ID (1) ID25449A (no)
IL (1) IL136867A0 (no)
IS (1) IS5542A (no)
JO (1) JO2065B1 (no)
MA (1) MA26587A1 (no)
NO (1) NO20003211L (no)
NZ (1) NZ505254A (no)
PA (1) PA8465101A1 (no)
PE (1) PE20000063A1 (no)
PL (1) PL341392A1 (no)
SK (1) SK9592000A3 (no)
SV (1) SV1998000151A (no)
TR (1) TR200001970T2 (no)
WO (1) WO1999032462A1 (no)
YU (1) YU39600A (no)
ZA (1) ZA9811725B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
DK1458386T3 (da) * 2001-12-27 2007-08-13 Ortho Mcneil Pharm Inc Aroylpyrrolheteroaryl- og methanolforbindelser til behandling af en lidelse i centralnervesystemet
SI1524981T1 (sl) * 2002-07-29 2009-08-31 Glaxo Group Ltd Glaxo Wellcome Formulacije z zadrĺ˝anim sproĺ äśanjem, ki vsebujejo lamotrigin
AU2004207009A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
DE10332472A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Tinnitus
PL1658062T3 (pl) * 2003-08-25 2010-07-30 Newron Pharm Spa Pochodne alfa-aminoamidu jako środki przeciwzapalne
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
EP3524605B1 (en) * 2018-02-13 2019-11-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. New efficient process for the preparation of sitagliptin
CN114796146B (zh) * 2022-04-28 2023-03-28 上海奥科达医药科技股份有限公司 一种拉莫三嗪的缓释制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
CS234018B2 (en) 1979-06-01 1985-03-14 Wellcome Found Method of 3,5-diammino-6-1,2,4-triazine derivatives making
JPS5625170A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
DE3069556D1 (en) 1979-08-16 1984-12-06 Wellcome Found Solid pharmaceutical formulation containing substitued phenyl-triazines
GB8328757D0 (en) 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
GB9012312D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9203483D0 (en) 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
IL105986A (en) 1992-06-12 1998-12-06 Wellcome Found Pharmaceutical preparations containing triazine compounds for the prevention or reduction of tolerable dependence or the opposite of dependency
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5866597A (en) 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305692D0 (en) 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
FR2741879A1 (fr) 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament

Also Published As

Publication number Publication date
CO5011066A1 (es) 2001-02-28
JO2065B1 (en) 2000-05-21
US6265405B1 (en) 2001-07-24
IL136867A0 (en) 2001-06-14
AU2414799A (en) 1999-07-12
AR014146A1 (es) 2001-02-07
PL341392A1 (en) 2001-04-09
SK9592000A3 (en) 2001-03-12
IS5542A (is) 2000-06-20
HN1998000193A (es) 2000-04-05
KR20010024800A (ko) 2001-03-26
AP2000001846A0 (en) 2000-06-30
BR9814495A (pt) 2000-10-10
TR200001970T2 (tr) 2001-01-22
AU753874B2 (en) 2002-10-31
CA2315620A1 (en) 1999-07-01
SV1998000151A (es) 1999-07-05
PA8465101A1 (es) 2000-09-29
GB9726987D0 (en) 1998-02-18
WO1999032462A1 (en) 1999-07-01
MA26587A1 (fr) 2004-12-20
JP2001526275A (ja) 2001-12-18
NO20003211D0 (no) 2000-06-21
ID25449A (id) 2000-10-05
CN1284951A (zh) 2001-02-21
ZA9811725B (en) 2000-06-27
PE20000063A1 (es) 2000-02-16
EE200000391A (et) 2002-02-15
YU39600A (sh) 2002-11-15
HUP0100611A2 (hu) 2001-09-28
EP1042304A1 (en) 2000-10-11
US6465461B1 (en) 2002-10-15
HRP20000419A2 (en) 2000-12-31
HUP0100611A3 (en) 2003-03-28
NZ505254A (en) 2002-06-28
GT199800203A (es) 2000-06-14
EA200000561A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
MY117896A (en) Quinazoline derivatives
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
MY136685A (en) Thiazole derivatives for treating ppar related disorders
IL107184A (en) Heterocyclic ether compounds that enhance cognitive function
BG106586A (en) Pyrazolopyramidines as therapeutic agents
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
MX9800187A (es) Compuestos de benzolactama substituidos como antagonistas de la substancia p.
BG106493A (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor
NO972307L (no) Matriksmetallproteaseinhibitorer
YU73802A (sh) Postupak sinteze perindoprila i njegovih farmaceutski prihvatljivih soli
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
NO996108L (no) 9-oksinerytromycinderivater
IL134089A0 (en) 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring
NO20015172L (no) 1-metyl-erytromycin-derivater
NO20003211L (no) Triazinforbindelser for behandling av CNS forstyrrelser
CA2192975A1 (en) Benzimidazolone Derivatives
NZ512292A (en) Sulfonamide hydroxamates that inhibit procollagen C- proteinase
NO930520L (no) Bifenyl-substituerte kinolinderivater
NO981393L (no) Guanidinoproteasehemmere
BG104575A (en) Matrix metalloprotease inhibitors
MX9702259A (es) Derivados de quinoxalina utiles en terapia.
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus